Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

A case report of a premature infant with haemophilia A and factor VIII inhibitor.

20:23 EDT 23rd July 2014 | BioPortfolio

Summary of "A case report of a premature infant with haemophilia A and factor VIII inhibitor."

No Summary Available

Affiliation

Neonatal Unit, St James's Hospital, Leeds, UK Department of Paediatric Haematology, Children's Day Hospital, St. James's University, Hospital, Leeds, UK.

Journal Details

This article was published in the following journal.

Name: Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Pages:

Links

PubMed Articles [23312 Associated PubMed Articles listed on BioPortfolio]

A case of acquired hemophilia caused by factor VIII inhibitor with rheumatoid arthritis, successfully treated with immunosuppressive treatment and recombinant activated factor VII.

Abstract We report the case of a patient who presented with acquired hemophilia associated with rheumatoid arthritis. The patient's factor VIII activity was less than 1% and factor VIII inhibitor was...

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A.

Electroconvulsive therapy (ECT) is used for medication-resistant and life-threatening mental disorders, and therefore it occupies an important position in psychiatric treatment. ECT reportedly increas...

Anomalous origin of one pulmonary artery from the ascending aorta (hemitruncus) in a premature infant: A case report and literature review.

Anomalous origin of one pulmonary artery from the aorta (AOPA) is a rare congenital anomaly. Here, we report the case of a premature infant with a delayed diagnosis of AOPA who died before surgical re...

Musculoskeletal evaluation in severe haemophilia A patients from Latin America.

There is a paucity of literature on haemophilia treatment in Latin American countries, a region characterized by rapidly improving systems of care, but with substantial disparities in treatment betwee...

Challenges for new haemophilia products from a manufacturer's perspective.

The development of new and improved therapeutic options for the management of haemophilia is a great challenge for both physicians and manufacturers. After factor VIII concentrates became widely avail...

Clinical Trials [2361 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of Recombinant Factor VIII (N8) in Male Children Previously Treated With Haemophilia A

This trial is conducted in Asia, Europe, Japan and the United States of America (USA). The aim of this clinical trial is to investigate the safety and efficacy of N8 in male previously tr...

Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

This trial is conducted in Europe and Asia. The aim of this clinical trial is to compare two recombinant factor VIII drugs, N8 with Advate®, in haemophilia A subjects, investigating the a...

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX

This study is conducted in the United States of America (USA). The aim of this study is to investigate the at-home-administration of bypassing agents for treatment of bleeding episodes in...

Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543 and NN7008-3545

This trial is conducted in Asia, Europe, Japan, Oceania, North America and South America. The aim of this clinical trial is to investigate safety and efficacy of N8 in Haemophilia A patie...

Kogenate Liplong Study - BAY 79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

A study to assess treatment with a new formulation of recombinant factor VIII reconstituted with liposomes (BAY79-4980) to evaluate whether a once-a-week treatment is safe and can prevent...

Medical and Biotech [MESH] Definitions

Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.

Activated form of factor VIII. The B-domain of factor VIII is proteolytically cleaved by thrombin to form factor VIIIa. Factor VIIIa exists as a non-covalent dimer in a metal-linked (probably calcium) complex and functions as a cofactor in the enzymatic activation of factor X by factor IXa. Factor VIIIa is similar in structure and generation to factor Va.

A human infant born before 37 weeks of GESTATION.

Onset of OBSTETRIC LABOR before term (TERM BIRTH) but usually after the FETUS has become viable. In humans, it occurs sometime during the 29th through 38th week of PREGNANCY. TOCOLYSIS inhibits premature labor and can prevent the BIRTH of premature infants (INFANT, PREMATURE).

Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).

Search BioPortfolio: